Cytosine base editing achieves robust lipoprotein(a) reduction while preserving genomic integrity
- 15 May 2026
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 34 (6) , 3152-3154
Abstract
No abstract availableFunding Information
- Deutsche Forschungsgemeinschaft (KL 3224/4-1)
- Else Kröner-Fresenius-Stiftung (KA 5060/5-1)
- Else Kröner-Fresenius-Stiftung (KA 5060/1-1)
- Else Kröner-Fresenius-Stiftung (2024_EKEA.34)
This publication has 10 references indexed in Scilit:
- Cytosine base editing of LPA in transgenic mice averts large deletionsMolecular Therapy, 2026
- Gene therapy and genome editing for lipoprotein disordersEuropean Heart Journal, 2025
- Targeting Lipoprotein(a) — the Next Frontier in Cardiovascular DiseaseNew England Journal of Medicine, 2025
- Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and ProspectsCirculation, 2025
- Large DNA deletions occur during DNA repair at 20-fold lower frequency for base editors and prime editors than for Cas9 nucleasesNature Biomedical Engineering, 2024
- Lipoprotein(a) and cardiovascular diseaseThe Lancet, 2024
- High lipoprotein(a): Actionable strategies for risk assessment and mitigationAmerican Journal of Preventive Cardiology, 2024
- LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept studyMolecular Therapy - Methods & Clinical Development, 2022
- In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primatesNature, 2021
- Lipoprotein(a) Reduction in Persons with Cardiovascular DiseaseNew England Journal of Medicine, 2020